Oranssibio
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An integrated CRO+CDMO platform providing end-to-end cell and gene therapy development and manufacturing services.
OncologyImmunology
Technology Platform
Integrated suite of six CGT platforms: mRNA-LNP, Lentivirus, Plasmid, AAV, Exosome, and Cell therapy, enabling end-to-end development and GMP manufacturing services.
Opportunities
Capitalizing on the global surge in CGT development and the critical shortage of GMP manufacturing capacity, particularly for viral vectors and cell therapies, by offering an integrated, faster, and globally compliant service from China.
Risk Factors
Intense competition from larger, established global CDMOs (e.g., Lonza, Catalent) and other Chinese CGT CDMOs; execution risk in maintaining consistent quality and speed across complex projects; regulatory and geopolitical complexities in serving a global client base.
Competitive Landscape
Competes with global CGT CDMOs like Lonza, Catalent, and Thermo Fisher's Patheon, as well as Chinese peers such as WuXi Advanced Therapies and Geneception. Differentiation is based on its integrated CRO+CDMO model, full-spectrum CGT platform capabilities, and claimed faster project delivery from its Shanghai facility.